Nova Patents
NO20060596L

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Abstract

Indazole compounds are described which modulate and / or inhibit the activity of certain protein kinases having formula III: wherein: r 'is C 6 -C 14 aryl or C 2 -C 9 heteroaryl, or a group of formula CH = CH-R 6 or CH = NR 4, wherein R 2 is C 1 -C 12 alkyl, C 3 -C 12 cycloalkyl, C 2 -C 9 heterocycloalkyl, C 6 -C 12 aryl or C 2 -C 9 heteroaryl; Y is O, S, C = CH 2, C = O, S = O, S, SO 2, CHCH 3, NH, or V 1 - (C 1 -C 8 alkyl); R * is C 1 -C 12 alkyl, C 2 -C 12 alkyl, C 3 -C 12 cycloalkyl, C 2 -C 9 heterocycloalkyl, C 6 -C 12 aryl, C 2 -C 9 heteroaryl, C 1 -C 12 alkoxyl or C 6 -C 8 aryloxyl; R 10 is independently selected from hydrogen, halogen and C 1 -C 6 alkyl; wherein each of the R 1, R 3 and R 9 groups may be optionally substituted by halogen, C 1 -C 6 alkyl, -OH, -NO 2, -CN, -CO 2 H, -O- (C 1 -C 8 alkyl), -C 6 -C 14 aryl - C 6 -C 11 aryl-C 1 -C 8 alkyl, -CO 2 CH 3, -CONH 2, -OCH 2 CONH 2, -NH 2, -SO 2 NH 2, haloalkyl or -O-haloalkyl; or a pharmaceutically acceptable salt thereof. These compounds, and their pharmaceutical materials, are capable of mediating tyrosine kinase signaling, thereby modulating and / or inhibiting unwanted cell proliferation. The invention also relates to the therapeutic and prophylactic use of pharmaceutical materials containing such compounds, to treat cancer and also to other forms of disease associated with undesirable angiogenesis and / or cellular progression, such as diabetes retinopathy, neovascular glaucoma, rheumatoid arthritis and psoriasis.

NO20060596L, drawing sheet 1
Sheet 1 of 1

Term

No projected expiry on record.

  1. Priority
  2. Published
  3. Filed
  4. Today

1 claim: 1 independent, 0 dependent

  1. 1
    H ra Hra